Adoptive cell transfer (ACT) using chimeric antigen receptor (CAR)‐modified T cells can
induce durable remissions in patients with refractory B‐lymphoid cancers. By contrast …

The broad success of adoptive immunotherapy to treat human cancer has resulted in a
paradigm shift in modern medicine. Modification of autologous and allogenic immune cells …

Despite remarkable success in the treatment of hematological malignancies, CAR T-cell
therapies for solid tumors have floundered, in large part due to local immune suppression …

Most studies on genetic engineering technologies for cancer immunotherapy based on
allogeneic donors have focused on adaptive immunity. However, the main limitation of such …

Engineered T cell receptor T (TCR-T) cell therapy has facilitated the generation of
increasingly reliable tumor antigen-specific adaptable cellular products for the treatment of …

Immune checkpoint inhibitors have redefined the treatment of cancer, but their efficacy
depends critically on the presence of sufficient tumor-specific lymphocytes, and cellular …

Adoptive transfer of T cells expressing a transgenic T cell receptor (TCR) has the potential to
revolutionize immunotherapy of infectious diseases and cancer. However, the generation of …

Adeno-associated virus (AAV) vectors have gained tremendous attention as in vivo delivery
systems in gene therapy for inherited monogenetic diseases. First market approvals …

In recent years, much research has been focused on the field of adoptive cell therapies
(ACT) that use native or genetically modified T cells as therapeutic tools. Immunotherapy …

The increasing burden on human malignant diseases became a major concern for
healthcare practitioners, that must deal with tumor relapse and the inability to efficiently treat …